Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect microneedle therapy showed encouraging results in treating basal cell carcinoma, ...
CEO Dr. Raza Bokhari talked with Proactive about the company’s newly reported topline Phase 2 results for its microneedle ...
Medicus Pharma Ltd. MDCX shares surged to a high of $1.61 before falling during Thursday’s premarket session following the ...
SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer ...
Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...
Gordon Ramsay is one of the most popular chefs in the world. Along with his cooking finesse he is also a vocal health ...
Hosted on MSN
Pictures of What Skin Cancer Looks Like
Skin cancer is a type of cancer that begins in the skin cells, and its appearance can vary widely depending on the type of cancer. Understanding the variations in what skin cancer looks like can help ...
Basal cell carcinoma (BCC) represents the most prevalent form of skin cancer, with research efforts increasingly focused on elucidating its molecular underpinnings and improving therapeutic strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results